Core Viewpoint - Company plans to apply for a funding limit of up to 3 billion HKD for potential cryptocurrency purchases, aiming to enhance its "Global Enhanced Ethereum (ETH) Treasury" strategy and accelerate the tokenization ecosystem of medical innovation drug intellectual property [1] Group 1: Strategic Upgrade - The board previously approved a maximum of 880 million HKD for purchasing Ethereum as a strategic reserve, with the first batch of 5,190 ETH acquired for a total price of 149 million HKD at an average cost of approximately 28,798 HKD (3,661 USD) per unit [1] - The new announcement seeks to increase the funding limit to 3 billion HKD, positioning the company as a leader in Ethereum reserves among listed companies in Hong Kong and globally [1] - The company emphasizes that the acquisition plan will strictly adhere to the regulatory framework for virtual assets in Hong Kong, ensuring asset safety and liquidity through compliant channels [1] Group 2: Ecological Synergy - The cryptocurrency strategy is closely tied to the company's core business of tokenizing medical innovation drug assets (RWA), utilizing its self-developed Web3 exchange ivd.xyz to convert high-value medical assets into tradable digital certificates [2] - Ethereum serves as the underlying infrastructure, providing value anchoring for RWA and generating staking income to support the treasury's growth [2] - The company has implemented a "seven-layer downside protection mechanism" and a "three-tier income enhancement engine" to safeguard shareholder interests amid market volatility [2] Group 3: Market Response - Following the announcement of the first ETH purchase, the company's stock price surged over 91% within a month, with a market capitalization exceeding 15 billion HKD, making it a focal point in the Hong Kong medical sector [3] - Market analysis indicates that the company's dual-driven model of "crypto treasury + medical RWA" aligns with valuation logic seen in leading Ethereum companies in the US, while offering greater industrial synergy [3] - The company has established a strategic partnership with BGI Win-Win Fund to acquire quality innovative drug pipelines, further enhancing the asset base of the ivd.xyz exchange [3] Group 4: Compliance First - The company reiterated that all cryptocurrency transactions will be conducted exclusively on regulated platforms, seeking independent approval at the shareholder special meeting to ensure transparency [3] - If the 3 billion HKD application is approved, the authorization will be valid for 36 months, allowing the board to execute the purchase plan in phases based on market conditions [3] - As traditional medical companies explore digital transformation, the company's innovative model of "Ethereum treasury + medical RWA" opens new pathways for asset allocation and value reassessment in the industry [3]

Core Viewpoint - The recent surge in the stock price of Huajian Medical (01931.HK) is attributed to its innovative strategic initiatives, particularly the establishment of an Ethereum reserve and the launch of a new trading platform for tokenizing medical assets, which has garnered significant investor interest and market recognition [1][2][18]. Group 1: Company Strategy and Market Performance - Huajian Medical's stock price increased approximately 120% in July and over 91% in August, leading to a market capitalization exceeding HKD 15 billion [1]. - The company announced a strategic initiative to create an Ethereum reserve and a trading platform (ivd.xyz) aimed at tokenizing medical assets, which is expected to enhance its valuation and growth potential [1][2][10]. - The company has already purchased 5,190 Ethereum at a cost basis of USD 3,661 each, realizing a profit of approximately USD 330,000 as Ethereum's price surpassed USD 4,300 [1][2]. Group 2: Investment Perspective - Huajian Medical is positioned as a unique investment opportunity in the Hong Kong market, combining elements of cryptocurrency, healthcare, and Real World Assets (RWA) [2][10]. - The Ethereum reserve strategy is expected to provide a solid value foundation for the company's future growth, as Ethereum has seen a cumulative increase of over 70% since July [2][4]. - The company’s approach to continuously invest in Ethereum through a dollar-cost averaging strategy may lead to further valuation premiums as the cryptocurrency market evolves [7][8]. Group 3: RWA and Tokenization - RWA refers to the tokenization of real-world assets, allowing for digital representation and trading of various tangible and intangible assets on blockchain networks [10][13]. - Huajian Medical's initiative to tokenize innovative drug assets aims to enhance liquidity and broaden financing channels, making it easier for investors to participate in the medical innovation sector [14][15]. - The company's trading platform is designed to convert intellectual property related to innovative drugs into tradable tokens, addressing traditional financing challenges in the healthcare industry [15][16]. Group 4: Industry Implications - The strategic moves by Huajian Medical could potentially transform the medical industry by promoting digitalization and asset securitization, thereby accelerating the drug development process and improving overall industry efficiency [15][17]. - Collaborations with industry leaders, such as HashKey Group and BGI, are expected to enhance the management of Ethereum reserves and support the establishment of a tokenized fund for innovative drug intellectual property [16][17]. - The company's innovative model may set a new benchmark in the Hong Kong market, attracting more international investment into domestic innovative drug development [9][18].